AI Cant Be Named as an Inventor on Drug PatentsUntil Congress Says Otherwise
What do drug developers, patent lawyers, and AI builders have in common right now? A growing mismatch between whats technologically possible and what the patent system legally…

Google Patents Wasnt Built for PharmaHeres What It Misses Every Time You Search a Drug Name
Most people search Google the way they search for truth: type a name, hit enter, and assume the system will surface what matters.
But if youre in pharmaregula…

Google Patents Wasnt Built for PharmaHeres What It Misses Every Time You Search a Drug Name
Most people search Google the way they search for truth: type a name, hit enter, and assume the system will surface what matters.
But if youre in pharmaregula…

Manual cross-referencing is quietly becoming one of the most expensive line items in modern patent strategyespecially when its hiding behind free data.
Lets talk about the free patent database problem. Not the absence of cost, but the cost of time, ris…

A spreadsheet of patent expirations doesnt make a strategyit creates a liability with a due date.
Heres the uncomfortable truth: in pharma, knowing what expires when is necessary, but its never sufficient. A static list of dates can feel like controlun…

Most nothing is urgent delays are really workflow design flaws in disguise.
Thats the real story behind The Analyst Report That Took Three WeeksShould Have Taken Three Hours: Heres the Bottleneck. Its a tale that will feel familiar to anyone who has ev…

Regulatory quarterly review doesnt just miss patentcompanies miss the timing. Thats why they keep losing NCE-1 dates.
Every year, the same pattern repeats across pharma: companies rely on the quarterly review process as a backstop, then act surprised w…

Stop Searching Patents. Start Asking Them Questions.
If youve ever done patent diligence by keyword searching a database and exporting a spreadsheet, youre not alone. But you might be missing the most important part of the exercise: interpretation.
Bec…

Still reading PACER by hand? The real cost isnt the timeits the lost advantage.
In competitive intelligence, speed isnt a nice to have. Its the difference between knowing a risk exists and being the person who can actually do something about it.
A lot …

Drugpatentwatchs Three-Clock Problem: Why Patent Expiration Dates Dont Predict Generic Launches
Most healthcare executives and investors have fallen into the same trap: you see a patent expiration date on a spreadsheet, run a clean timeline, and assume…